CDH1 Genotype

Some inherited cancer risks hide from everything a normal checkup measures. This gene is one of them. A single inherited change in it can raise your lifetime odds of a stomach cancer that spreads through the wall without forming a lump, and a specific type of breast cancer that is hard to see on a routine mammogram.

Knowing your status here does not change with age or lifestyle. It is a permanent answer written in your DNA. If you carry a harmful version, it reshapes how closely you and your blood relatives should be watched, and it can move decisions years before any cancer would otherwise be found.

What This Gene Does

This test reads your CDH1 (cadherin 1) gene, which sits on chromosome 16 and holds the recipe for E-cadherin, a protein that acts like molecular velcro between the cells that line your organs. E-cadherin keeps these lining cells stuck to their neighbors, holds tissue in an orderly sheet, and helps control when cells divide or move.

When both copies of this velcro protein are lost inside a cell, that cell can drift away from its neighbors and invade. This is why the two cancers most tied to harmful CDH1 changes, diffuse stomach cancer and lobular breast cancer, both grow in a scattered, non-clumping pattern rather than as a single solid mass. The test measures your inherited DNA sequence, and from that it signals whether your E-cadherin safety system was built with a permanent flaw.

A key distinction runs through everything below. A clearly harmful, protein-truncating change (called pathogenic or likely pathogenic) is what carries real cancer risk. A change of uncertain meaning (a variant of uncertain significance) is a different thing entirely, and in the largest genotype-first study these uncertain missense changes showed no positive link to the classic cancers.

Diffuse Stomach Cancer

The oldest and best-established link is to hereditary diffuse gastric cancer, a syndrome named for the way this stomach cancer spreads diffusely instead of forming a discrete tumor. Older studies of families selected specifically because they had many gastric cancers estimated lifetime risk by age 80 as high as 70% in men, and in some analyses up to about 83% in women.

More recent North American modeling found that the risk of advanced stomach cancer (stage II or higher) was substantially lower, closer to 1 in 10 for men (10.3%) and roughly 1 in 15 for women (6.5%) by age 80. Nearly all carriers still harbor at least early, superficial disease, and current guidelines put overall gastric cancer risk at roughly 25% to 42% depending on sex. The gap between the old and new headline numbers is not a contradiction, and the next section explains why.

Why the Risk Numbers Disagree

This is not a case of one study being right and another wrong. It is a phenotype indicator whose measured risk depends heavily on how the families were found and on which cancers are counted. When researchers start with families already flooded with stomach cancer, the carriers in those families carry extra unmeasured risk, so penetrance looks very high. When researchers instead find carriers through broad gene panels, without pre-selecting for stomach cancer, and focus on advanced disease, the same variant looks much less penetrant. Your own risk sits somewhere on this spectrum, pushed higher by a strong family history and lower by its absence. The practical takeaway is that your family tree is part of the result, not separate from it.

Lobular Breast Cancer

For women, breast cancer risk is the other major, well-supported association, and it has held up as a substantial number across studies even as the stomach estimates dropped. Recent modeling put lifetime breast cancer risk for female carriers near 37% (36.8%), while older large series reported around 42%, and a clinically ascertained cohort reported as high as 55%. The type is specifically invasive lobular breast cancer, which grows in single-file lines of cells and can evade detection on a standard mammogram.

Lobular breast cancer is such a strong signal that a genotype-first European analysis found it carried the largest association of any phenotype examined, with carriers of harmful variants about 12 times as likely to have lobular breast cancer as families with only uncertain variants (odds ratio 12.39). A meaningful minority of families with harmful CDH1 variants have breast cancer only and no gastric cancer at all, and in one cohort of women with lobular breast cancer, 1.5% carried a harmful CDH1 variant, often without meeting the classic stomach-cancer testing rules.

What this means for you: do not anchor on a single percentage. A harmful result is best read as a meaningful, lifelong elevation in diffuse stomach and lobular breast cancer risk, with the exact magnitude set by your family history and confirmed variant classification.

Associations Still Being Sorted Out

Beyond stomach and lobular breast cancer, the evidence thins out. A large testing-database study found harmful CDH1 variants enriched among people with colorectal signet-ring cancers and gastric and breast cancers, but a multicenter analysis of carriers found colorectal growths at rates similar to the general population. Common, everyday CDH1 spelling differences (polymorphisms) have been linked in specific Asian populations to sporadic stomach cancer risk, colorectal cancer risk, and cancer survival, but these are population association studies, not the basis for inherited-risk counseling.

In colorectal cancer, one common CDH1 variant has repeatedly predicted worse survival even after accounting for other prognostic factors, with a roughly 28% higher risk of dying (hazard ratio 1.28) concentrated in advanced disease. There is no established association between this gene and heart disease, stroke, or death from causes other than cancer. Cleft lip or palate has appeared in some affected families, tied to E-cadherin's role in early facial development.

A One-Time Test You Act On for Life

Because your DNA sequence at this gene does not change, this is a once-in-a-lifetime test. There is no trend to track and no reason to repeat the genotype itself, unless a laboratory calls a result with low confidence and a confirmatory method is needed. The value comes from what you do with the answer over the decades that follow, not from retesting.

If you carry a harmful variant, the tracking that matters shifts to your body, not your DNA. That means earlier and more frequent stomach surveillance, breast imaging that adds MRI to annual mammography, and ongoing conversations about risk-reducing options. If your result is negative or an uncertain variant, the useful follow-up is periodic re-checking of that variant's classification with your genetics clinician, since uncertain findings can be reclassified as science advances.

When a Result Can Mislead You

Unlike a blood level, a genotype is not thrown off by food, exercise, or the time of day. The traps here are different and specific to genetic testing:

• Uncertain variants read as harmful: a variant of uncertain significance should not drive surgery or major management. In one survey, some people reported an uncertain variant as if it were pathogenic, and labs disagreed with each other in about 13% of cases. Confirm the exact classification before acting.
• A negative result is not a clean bill: the test only detects the specific changes it is designed to find. Some families carry large deletions missed by standard sequencing, and adding deletion testing raised detectable CDH1 changes to 46% of families in one series. A negative result does not rule out every rare change or other cancer genes.
• Criteria are not the same as genotype: many true carriers fall outside classic testing rules. In one panel-testing cohort, 65% of carriers did not meet the older stomach-cancer criteria, so not fitting the checklist does not mean you are variant-free.
• Ancestry shapes meaning: some recurrent variants are founder mutations concentrated in specific regions or populations, so the clinical weight of a result depends partly on your background.

What to Do With an Unexpected Result

A confirmed harmful result should trigger a coordinated workup, not a single reaction. The first step is confirming the variant classification with a certified genetics clinician, ideally checking whether a second method (such as targeted sequencing after a chip-based call) is warranted. From there, the pathway branches by your sex, age, and family history.

Carriers are typically referred to both a gastroenterologist experienced in this syndrome and, for women, a breast specialist. Stomach surveillance uses specialized endoscopy with extensive biopsies, though carriers and clinicians should understand that endoscopy misses much early disease, detecting only about 45% of eventual signet-ring cancers in one cohort, which is why risk-reducing total gastrectomy is weighed through shared decision-making even when scopes look normal. For women, annual mammography with consideration of breast MRI is standard, and prophylactic mastectomy is part of the conversation. An uncertain variant, by contrast, generally warrants watchful reclassification rather than aggressive intervention.

The combination that most strongly favors action is a clearly pathogenic or likely pathogenic variant together with a family history of diffuse stomach or lobular breast cancer. A harmful variant with no family history still matters, since occult stomach cancer has been found in carriers without any family history, but the intensity of intervention is best weighed with a specialist.